Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Utility of Plasma Drug Level Monitoring and CYP2C19 Genotyping in Dose Personalization of Escitalopram

NCT05210140 is registered in ClinicalTrials.gov with University of Belgrade as lead sponsor.

NCT NCT05210140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05210140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Utility of Plasma Drug Level Monitoring and CYP2C19 Genotyping in Dose Personalization of Escitalopram
Lead sponsor
University of Belgrade
Phase
Observational
Overall status
Unknown status
Start date
July 16, 2020
Completion date
November 30, 2023
Enrollment
148 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major